Table 2.
Current clinical trials combining epitherapy with other cancer therapies in various cancer types
| Clinical trials identifier | Recruitment status | Phase | Cancer type | Epigenetic drug | Other drug |
|---|---|---|---|---|---|
| NCT03812796 | Recruiting | 2 | GI Cancer | Domatinostat (HDACi) | Avelumab |
| NCT02395627 | Active, not recruiting | 2 | Breast Neoplasms | Vorinostat (HDACi) | Pembrolizumab, Tamoxifen |
| NCT01928576 | Recruiting | 2 | Non-Small Lung Cancer | Azacitidine (DNMTi), Entinostat (HDACi) | Nivolumab |
| NCT02512172 | Active, not recruiting | 1 | Colorectal Cancer | Azacitidine, Istodax (HDACi) | Pembrolizumab |
| NCT02900560 | Recruiting | 2 | Epithelial Ovarian Cancer | Azacitidine | Pembrolizumab |
| NCT03220477 | Recruiting | 1 | Lung Cancer | Guadecitabine (DNMTi), Mocetinostat (HDACi) | Pembrolizumab |
| NCT02250326 | Active, not recruiting | 2 | Carcinoma, NSCLC | Azacitidine | Duravalumab, Nab-paclitaxel |
| NCT01845805 | Recruiting | 2 | Pancreatic Cancer | Azacitidine | Possibly Abraxane or Gemcitabine |
| NCT02489903 | Recruiting | 2 | Small Cell Carcinoma, NSCLC, Neuroendocrine Tumors, Ovarian Epithelial Cancer | RRx-001 | Cisplatin, Etoposide, Carboplatin, Paclitaxel, Nab-Paclitaxel, Pemetrexed |
| NCT02959437 | Active, not recruiting | 1/2 | NSCLC, CRC, HNSCC, Urothelial Carcinoma, Melanoma | Azacitidine, INCB059872 (LSD1 inhibitor) | Pembrolizumab, Epacadostat, INCB057643 |
| NCT02711956 | Active, not recruiting | 1/2 | Metastatic Castration-Resistant Prostate Cancer | ZEN003694 | Enzalutamide |
| NCT02497404 | Active, not recruiting | 2 | Acute Erythroblastic Leukemia, Myelodysplastic Syndromes | 5-Azacytidine | Fludarabine, Melphalan, Alemtuzumab, Radiation |
| NCT03901469 | Recruiting | 2 | Triple Negative Breast Cancer | ZEN003694 | Talazoparib |
| NCT03179943 | Recruiting | 2 | Urothelial Carcinoma | Guadecitabine (DNMTi) | Atezolizumab |
| NCT02518958 | Active, not recruiting | 1 | Malignant Solid Tumor, Lymphoma | RRx-001 | Nivolumab |
| NCT03843528 | Recruiting | 1 | Leukemias | Vorinostat, Azacitidine | None |
| NCT02724202 | Active, not recruiting | 1 | Metastatic Colon Cancer | Curcumin | 5-flurorouracil |
| NCT03505528 | Recruiting | 1 | Metastatic Breast Cancer | Phenelzine Sulfate | Nab-paclitaxel |
| NCT01627041 | Active, not recruiting | 2 | Acute Adult Leukemia | Decitabine (DNMTi) | Cytarabine and Daunorubicin |
| NCT03164057 | Recruiting | 2 | AML | Azacitidine or Decitabine | Cytarabine, Daunorubicin, Etoposide, Idarubicin, Fludarabine, Mitoxantrone, Filgrastim, Dexrazoxane, Erwinia asparaginase, Sorafenib |
| NCT02546986 | Active, not recruiting | 2 | Carcinoma, NSCLC | Azacitidine | Pembrolizumab |
| NCT03263936 | Recruiting | 1 | Acute Myelogenous Leukemia | Decitabine, Vorinostat | Filgrastim, Fludarabine, Cytarabine |
| NCT02717884 | Recruiting | 1/2 | AML, Myelodysplastic Syndrome | Tranylcypromine (LSD1 inhibitor) | All-trans Retinoic Acid (Vesanoid), Cytarabine |
| NCT01534598 | Recruiting | 1 | Neoplasms | 5-fluoro-2′-deoxycytidine (FdCyd) (DNMTi) | Tetrahydrouridine (THU) |
| NCT02951156 | Active, not recruiting | 3 | Diffuse Large B-Cell Lymphoma | Azacitidine | Avelumab, Utomilumab |
| NCT03417427 | Recruiting | 2 | AML | Decitabine | Ara-C (Cytarabine) |
| NCT03719989 | Not yet recruiting | 2 | Diffuse Large B Cell Lymphoma, Non-Hodgkin Lymphoma | Azacitidine | Rituximab-GDP |
| NCT03765229 | Recruiting | 2 | Melanoma | Entinostat | Pembrolizumab |
| NCT02452970 | Active, not recruiting | 2 | Cholangiocarcinoma | RRx-001 | Gemcitabine and Cisplatin |
| NCT03612739 | Not yet recruiting | 1 | AML | 5-Azacytidine | NKR-2 |
| NCT03709550 | Not yet recruiting | 1/2 | Prostate Carcinoma | Decitabine | Enzalutamide |
| NCT01700569 | Recruiting | 1 | Grade IV Astrocytoma, Glioblastoma | Folinic acid (DNA methylator) | Temozolomide, Radiation |
| NCT03903458 | Recruiting | 1 | Malignant Melanoma | Tinostamustine | Nivolumab |
| NCT04022005 | Not yet recruiting | 2 | Lymphoma, Large B-Cell, Diffuse | Chidamide (HDACi) | Rituximab, Gemcitabine, Oxaliplatin |
| NCT02085408 | Active, not recruiting | 3 | Leukemia | Clofarabine (DNA hypomethylator) with Decitabine | |
| NCT02842827 | Completed | 1 | AML, Myelodysplastic Syndrome | IMG-7289 (LSD1 inhibitor) | All-trans Retinoic Acid (Vesanoid) |
| NCT02273102 | Active, not recruiting | 1 | Acute Myelogenous Leukemia | Tranylcypromine (LSD1 inhibitor) | Tretinoin |
| NCT02712905 | Recruiting | 1/2 | Solid Tumors and Hematologic Malignancy | INCB059872, Azacitidine | All-trans Retinoic Acid, Nivolumab |
Abbreviations: NSCLC non-small cell lung carcinoma, HNSCC head and neck squamous cell carcinoma, AML acute myeloid leukemia, CRC colorectal cancer, DNMTi DNA methyltransferase inhibitor